Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

IL-1β inhibition reduces anaemia incidence, improves haemoglobin levels

03 Apr 2020

Inhibition of inflammation through the interleukin (IL)-1β/IL-6 pathway among anaemic patients leads to a decrease in anaemia incidence and an improvement in haemoglobin levels, reveals a recent study.

This exploratory analysis of a randomized controlled trial in clinical sites across 39 countries included 8,683 Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) participants without anaemia at trial entry and 1,303 with prevalent anaemia at trial entry. Patients were randomized to receive placebo or canakinumab (50, 150 or 300 mg) subcutaneously once every 3 months.

The primary outcome of incident anaemia (haemoglobin level <130 g/L in men or <120 g/L in women) increased with rising baseline levels of high-sensitivity C-reactive protein (hsCRP). Participants treated with canakinumab vs placebo showed decreased levels of hsCRP and IL-6.

Incident anaemia, during a median follow-up of 3.7 years, was significantly lower among participants without baseline anaemia who received canakinumab at any dosage compared with those who received placebo (hazard ratio, 0.84, 95 percent confidence interval, 0.77–0.93; p<0.001).

IL-1β inhibition was most beneficial on incident anaemia among participants with the strongest anti-inflammatory response as compared with placebo. Formal mediation analyses corroborated this effect.

Canakinumab vs placebo increased mean haemoglobin levels by 11.3 g/L (p<0.001) among individuals with baseline anaemia after 2 years of treatment. However, canakinumab was associated with an increased risk for infection and with mild cases of thrombocytopaenia and neutropaenia, none of which was grade 3.

“CANTOS was not designed to assess the cause of anaemia in individual trial participants,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.